This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tohgi, H. Articles by Suzuki, H. Search for Related Content PubMed PubMed Citation Articles by Tohgi, H. Articles by Suzuki, H.

Stroke, Vol 21, 1663-1667, Copyright © 1990 by American Heart Association

ARTICLES

Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism

H Tohgi, M Kawashima, K Tamura and H Suzuki
Department of Neurology, Iwate Medical University, Japan.

We assayed plasma concentrations of fibrinogen, fibrinopeptide A, plasmin-alpha 2 plasmin inhibitor complex, D dimer, and antithrombin III activity in 40 patients with cerebral thrombosis and nine patients with cerebral embolism during the acute (less than 7 days), subacute (7- 27 days), and chronic (greater than or equal to 28 days) periods and compared these with 69 controls. In cerebral thrombosis, fibrinogen and fibrinopeptide A levels were elevated significantly in all stages (p less than 0.001), whereas plasmin-alpha 2 plasmin inhibitor complex and D dimer levels were elevated significantly in the subacute and chronic periods. The antithrombin III activity was significantly decreased in the acute stage. The elevation of fibrinogen and plasmin-alpha 2 plasmin inhibitor complex levels in the acute stage was significantly greater in patients with an infarct size greater than 10 mm2 compared to patients with an infarct size less than 10 mm2. We observed similar changes in patients with cerebral embolism. These results suggest that enhanced coagulation exists at all stages and endogenous fibrinolysis is activated in the subacute and chronic periods in a large proportion of patients with cerebral thrombosis and embolism.

This article has been cited by other articles:

				J. Montaner, M. Perea-Gainza, P. Delgado, M. Ribo, P. Chacon, A. Rosell, M. Quintana, M. E. Palacios, C. A. Molina, and J. Alvarez-Sabin Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers Stroke, August 1, 2008; 39(8): 2280 - 2287. [Abstract] [Full Text] [PDF]

				A. J. Catto Genetic aspects of the hemostatic system in cerebrovascular disease Neurology, September 1, 2001; 57(90002): S24 - 30. [Abstract] [Full Text]

				C. D. Bushnell and L. B. Goldstein Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke Stroke, December 1, 2000; 31(12): 3067 - 3078. [Abstract] [Full Text] [PDF]

				M. Davis and D. Barer Neuroprotection in acute ischaemic stroke. II: Clinical potential Vascular Medicine, August 1, 1999; 4(3): 149 - 163. [Abstract] [PDF]

				A. Roden-Jullig, M. Britton, and J. Svensson Antithrombin-III Activity and the Efficacy of Heparin in Progressing Ischemic Stroke Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 129 - 132. [Abstract] [PDF]

				W. M. Feinberg, L. P. Erickson, D. Bruck, and J. Kittelson Hemostatic Markers in Acute Ischemic Stroke: Association With Stroke Type, Severity, and Outcome Stroke, August 1, 1996; 27(8): 1296 - 1300. [Abstract] [Full Text]

				A. Lindgren, C. Lindoff, B. Norrving, B. Astedt, and B. B. Johansson Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Stroke Patients Stroke, June 1, 1996; 27(6): 1066 - 1071. [Abstract] [Full Text]